Please ensure Javascript is enabled for purposes of website accessibility

Why Halozyme Therapeutics Inc. Shares Jumped

By Sean Williams - Sep 27, 2013 at 2:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Halozyme reaches a milestone, and Roche gladly opens up its wallet.

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics (HALO -2.29%), a biopharmaceutical company focused on developing human enzymes for clinical benefit purposes, jumped as much as 15% following the official launch of Roche's (RHHBY 0.53%) Herceptin SC in Europe.

So what: Why does this matter? Because Roche's newly approved subcutaneous injection of Herceptin -- which can be given in a fraction of the time that the standard IV can -- utilizes Halozyme's recombinant human hyaluronidase. As such, the official launch of Herceptin SC in Europe triggered a $10 million milestone payment from Roche to Halozyme, bumping Halozyme's net cash position up to $55 million (based on its most recent quarterly filing).  

Now what: Everyone loves a good milestone payment, but a $150 million market cap boost for a $10 million payment might be a bit steep. Expectations are high surrounding Herceptin SC -- as they should be -- since the drug could remarkably increase patient convenience. Now we need to see how well its launch is actually executed before we get too excited. I'd certainly advocate adding Halozyme Therapeutics to your watchlist, but as an investment at these levels I still see plenty of questions that are only going to be answered by watching and waiting a few quarters to see if sales take off.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.79 (0.53%) $0.22
Halozyme Therapeutics, Inc. Stock Quote
Halozyme Therapeutics, Inc.
HALO
$43.46 (-2.29%) $-1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.